Taking stock of the drug industry, from the lab to the medicine chestOctober 23, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Launch prices for new drugs 'significantly' exceed inflation and offer insufficient value, analysis says "Urgent action is needed to increase affordability and access to medicines," said Sarah Emond of ICER, the nonprofit that ran the analysis. By Ed Silverman STAT+ | Despite a tough year, Moderna forges ahead with cancer therapies At ESMO 2025, Moderna's oncology chief explains the company's mRNA-4359 compound and why its cancer ambitions remain strong despite setbacks. By Andrew Joseph STAT+ | Time is running out for Anavex and its treatment for Alzheimer's disease Advisers to the European Medicines Agency will certainly recommend against the approval of Anavex's drug for Alzheimer's, called blarcamesine. By Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments